Larimar Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Larimar Therapeutics, Inc. (LRMR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-80.60-36.95-35.36-50.64-42.48
Depreciation & Amortization0.320.310.320.310.16
Stock Based Compensation8.807.626.625.472.16
Change in Working Capital6.18-2.511.672.73-2.04
Change in Accounts Payable1.14-0.400.03-0.97-3.29
Change in Other Working Capital5.03-0.081.640.021.25
Other Operating Activities-5.45-0.08-0.055.492.14
Net Cash from Operating Activities-70.76-33.46-27.57-42.11-42.20
Investing Activities
Capital Expenditures-0.52-0.16-0.100.33-0.06
Acquisitions0.000.000.000.0040.64
Purchases of Investments-227.87-101.23-90.86-8.25-23.49
Sales/Maturities of Investments143.00134.75-90.8624.50-24.78
Other Investing Activities0.000.000.000.00-1.30
Net Cash from Investing Activities-85.3933.35-90.9624.1717.09
Financing Activities
Common Stock Issued161.810.0375.2619.8993.59
Other Financing Activities0.080.000.000.0018.00
Net Cash from Financing Activities161.880.0375.2619.8993.59
Summary
Net Change in Cash5.74-0.08-43.271.9568.48
Cash at Beginning of Period28.0928.1671.4469.491.01
Cash at End of Period33.8228.0928.1671.4469.49
Free Cash Flow-71.28-33.62-27.67-42.44-42.26